2023 Volume 13 Issue 4 Pages 22-27
Pulmonary amyloid light-chain (AL) amyloidosis is rarely symptomatic or needs treatment. We herein report a case of a 72-year-old man with diffuse alveolar-septal AL amyloidosis that was difficult to distinguish from bortezomib-induced lung disease because symptoms and ground-glass opacities on CT appeared after the administration of bortezomib. Based on pathological findings of the resected lung, a diagnosis of pulmonary amyloidosis was made. The patient also developed a spontaneous pulmonary hematoma and pneumothorax during the course of therapy. However, treatment with lenalidomide and low-dose dexamethasone was successful. This case provides insights into the clinical features and management of pulmonary AL amyloidosis.
